Skip to main content

Table 1 COVID-19 patient characteristics (n = 36)

From: Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses

Cohort characteristics

no.

%

Male

25

69

Age, years, median (range)

60.5 (25–77)

Symptom onset to sampling, days, median (range)

18 (9–53)

Days since diagnosis (positive SARS-CoV-2 PCR), median (range)

8 (1–44)

Comorbidities

 Diabetes mellitus type II

13

36

 Hypertension

11

31

 Lung disease

8

22

 Cardiovascular disease

7

19

 BMI > 25

6

17

 Malignancy

3

8

Treatment

 Supplemental oxygen

33

92

 Mechanical ventilation

9

25

 ICU addmissiona

14

39

 Immunomodulatory drugsb

14

39

 Antiviral treatment (remdesivir)

2

6

  1. aICU addmission before study sampling (n = 11), ICU treatment during study sampling (n = 2), ICU treatment after study sampling (n = 1)
  2. bTreatment before sampling corticosteroids (n = 13), tociluzimab (n = 2) or anakinra (n = 1). Two patients had prednisolone treatment before COVID-19 and had extra corticosteroids added as treatment